A new RIVM risk assessment identifies #AMR as the leading international public health risk for the Netherlands over the coming decade & recognizes that tackling AMR requires stronger preparedness, international collaboration & continued investment in antibiotic R&D. 📖 www.rivm.nl/publicaties/...

GARDP has signed a memorandum of understanding with ILDONG Pharmaceutical to explore how to strengthen future supply and access pathways for flomoxef, an antibiotic being studied for neonatal sepsis.

We're hiring! GARDP is looking for a Consultant – Medical Affairs & Clinical Coordination in Delhi to support access to a priority antibacterial treatment through clinical evidence, regulatory engagement and expert collaboration. 📍 Delhi | 📅 6-month consultancy (extendable) 📩 aroy@gardp.org

For decades, the global pipeline for developing and delivering new antibiotics has worked in reverse. In his latest @telegraph.co.uk op-ed, Peter Beyer explains how Thailand's fast-track approval of zoliflodacin could help turn that model on its head. 🔗 www.telegraph.co.uk/global-healt...

New drug for super-gonorrhoea points to better antibiotic development

It is possible to break the cycle that has left much of the world waiting years for new antibiotics

telegraph.co.uk

In Luska, Zambia, alongside #RAAC2026, GARDP brought together government representatives, researchers, clinicians, advocates and AMR experts to help inform its 2027–2031 strategy. The most effective solutions are grounded in regional expertise and shaped by those closest to the challenge.

🚨 This is BIG! The Thai FDA has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea, just 6 months after its initial approval by the US FDA. 🔗 gardp.org/thai-fda-app...

✨ We've got a fresh new look! The new GARDP website is live — our biggest digital evolution since we were founded. Explore our programmes, projects, research, stories and more through a faster, more intuitive experience. 🌐 gardp.org Bacteria are evolving. So must we. #AMR #GlobalHealth

Experience #ICID2026 in Madrid this November! Explore a multidisciplinary programme covering AI, genomic surveillance, One Health, AMR, research equity, and more. 🔗 Scientific Programme: https://ow.ly/e9pi50ZnE99 ⏰ Early Bird ends 30 July: https://ow.ly/jYI050ZnE96 #ISID #GlobalHealth

⚠️ People across Latin America and the Caribbean face delays in accessing Reserve antibiotics, even after these medicines have been approved elsewhere. Our new review explores why, and highlights opportunities to improve access through coordinated regional action. 🔗 Read: tinyurl.com/4xjm5ay9

A major milestone for GARDP's #NeoSep1 trial 🎉 The first baby has now been enrolled in Vietnam, continuing the expansion of this landmark neonatal sepsis trial from Africa into Asia.

REVIVE was created by GARDP to preserve critical AMR expertise and connect the global antimicrobial R&D community. Explore the platform and discover resources designed to support antimicrobial innovation. 🔗 https://gardp.pulse.ly/z48xmfdeso

📢Late-breaker abstract submissions are now open for #GAMRIC2026! 📩 Submit your abstract: www.gamric.org/programme/ab... 🎟️ Register by 15 July (tomorrow) to secure the early registration rate: www.gamric.org/registration... @escmid.bsky.social

🤝 GARDP has signed an MoU with Venus Remedies Limited under the India AMR Co-Development Programme (I-AMR-CDP). As a Knowledge Partner, we'll contribute scientific expertise to help evaluate promising antibacterial candidates emerging from India's research ecosystem.

🚨 Late-breaker abstract submissions are now open for #GAMRIC2026! Submit by 22 July. ⏰ Don't forget: the early registration deadline is 15 July. 📝 Abstracts: https://gamric.pulse.ly/ojkyzslkik 🎟️ Register: https://gamric.pulse.ly/1cw3wtn5e6 @escmid.bsky.social

The antibiotics we need most are often the hardest to develop. A new BBC StoryWorks feature explores why antibiotic innovation needs a new model, and highlights GARDP's public health-driven approach to R&D, access and stewardship. Read more: www.bbc.com/storyworks/i...

Antimicrobial resistance is on the rise. Can prevention outpace antimicrobial resistance?

Antimicrobial resistance is on the rise. Can prevention outpace antimicrobial resistance?

bbc.com

#NeoSep1 has officially expanded to Pakistan! 🇵🇰 We are proud to be a partner in this innovative clinical trial, improving antibiotic treatment options for newborns with sepsis. @gardp.bsky.social @innovative-ctu.bsky.social @citystgeorges.bsky.social

Global Antibiotic R&D Partnership (GARDP)@gardp.bsky.social · last mo.

Every year, millions of newborns develop sepsis. For many, the antibiotics available are no longer effective. We're proud to announce the launch of the #NeoSep1 clinical trial at Aga Khan University Hospital in Pakistan, helping advance better treatment options for newborns with sepsis. #AMR

Every year, millions of newborns develop sepsis. For many, the antibiotics available are no longer effective. We're proud to announce the launch of the #NeoSep1 clinical trial at Aga Khan University Hospital in Pakistan, helping advance better treatment options for newborns with sepsis. #AMR

📢 GARDP has joined 7 other Product Development Partnerships in calling for sustained investment in EDCTP under FP10 and other EU funding frameworks. 🔗 tinyurl.com/2t3tjbkk @globalhealthedctp3.bsky.social @ec.europa.eu @europevaccine.bsky.social @dndi.org @mmv.org @tballiance.bsky.social

Join the @who.int AMR Department and #GAPf on 22 July for an industry dialogue on evidence generation for antibiotics for children and newborns. Insights from the session will help inform upcoming WHO technical guidance. 📅 22 July 2026 🕑 14:00–15:30 CEST 🔗 Register: shorturl.at/Ps898

🚨 In a new @theguardian.com opinion piece, GARDP's Peter Beyer, writes that the rise in STIs in Europe is an early warning sign of a much bigger challenge: AMR is no longer confined to hospitals, they move with and among us, crossing cities, countries and continents. 📖 tinyurl.com/thmmwtmb

Join us at #GAMRIC2026, early registration closes in 15 days: www.gamric.org Don't miss out on the latest developments in the #AMR fight at the 2026 edition of GAMRIC where innovators from public and private sectors meet to discuss pragmatic solutions to the problems of today. @escmid.bsky.social

Gamric - Home

gamric.org

We’re excited to be involved with Mediaplanet on the Global Health Resilience campaign, launching in the Guardian and online. Follow the link to read more www.globalcause.co.uk/global-healt... #GlobalHealthResilience2026

📖 Our 2025 Annual Report is now available. A landmark achievement in 2025 was the US FDA approval of zoliflodacin, the first new treatment developed solely for gonorrhoea in decades and the first in GARDP's portfolio to receive regulatory approval. 📖 Read the report: gardp.org/gardps-2025-...

🚀 Help shape a global community for early-career researchers in antimicrobial R&D. If you're a student, PhD candidate, postdoc, clinician or early-career professional, take 8–10 min #REVIVE survey today. Senior researchers are welcome too! 🔗 https://office.pulse.ly/1nwkdbgjhe

💻Join the next #REVIVE webinar to explore how studying the highly specialized and flexible metabolic pathways that help mycobacteria survive under stress conditions could inform the development of new antimicrobials. 🗓️ 14 July 💬 Live Q&A 🔗 Register here: attendee.gotowebinar.com/register/529...

Together with the Government of the Netherlands, GARDP convened 90+ participants from EU institutions, Member States, industry and civil society in Brussels to discuss AMR as a preparedness, resilience and competitiveness challenge.

🚀We're excited to share our latest Antimicrobial Viewpoint, developed collaboratively with @cmicomms.bsky.social. In 'From fixed courses to flexible care', the authors explore why antifungal treatment durations and routes deserve rethinking. 🔗Read the Viewpoint: revive.gardp.org/from-fixed-c...

From fixed courses to flexible care - reconsidering antifungal treatment duration and route - by Ilana Reinhold, Rosanne Sprute, Jannik Stemler & Oliver A. Cornely

The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contr...

revive.gardp.org

News: @nature.com India reports on NeoSep1's expansion to Asia, with Indian hospitals joining the global trial to find safe, effective and affordable antibiotic combinations for neonatal sepsis. The trial aims to enrol 3,000 newborns across Asia and Africa by 2028. www.nature.com/articles/d44...

Researchers seek better antibiotics for newborn sepsis amid rising drug resistance

Indian hospitals join a global trial to find safe and affordable antibiotic combinations for the infections, which are currently treated by more than 200 regimens worldwide.

nature.com

With the G7 Summit in France bringing global challenges into focus, one question deserves attention: ⚠️ What would healthcare look like if antibiotics stopped working? Dr. Norio Ohmagari, infectious diseases specialist and health security expert in Japan, explains how #AMR is a growing reality.

🚨 This is BIG! 👶JIPMER in India enrolled the first baby in Asia into the NeoSep1 trial. Since then, babies have been enrolled at the Rohtak site, with Mumbai next. 🧪 Led by GARDP and partners, NeoSep1 is one of the most ambitious clinical trials ever undertaken for neonatal sepsis.